Gadoteridol

A gadolinium chelate with similar effects and uses to those of gadopentetic acid. Used as a contrast agent in magnetic resonance imaging. Administered intravenously.

As of the date of the last update, we found no published data on its excretion in breast milk.

The various gadolinium-based contrast agents used for magnetic resonance imaging (MRI) are considered compatible with breastfeeding because they are rapidly eliminated (elimination half-life of less than 2 hours) with minimal metabolism and are virtually unabsorbable when taken orally. They are structurally very similar to one another, and for some of them, there is data indicating no or minimal excretion into breast milk. Less than 1% of the dose administered to the mother ends up in breast milk. ^{(ACR 2026, Wang 2012)}

Due to their low oral bioavailability, intestinal absorption is less than 1% of any dose the infant may have ingested. ^{(Wang 2012)}

Most experts and scientific societies in radiology agree that there is no need to wait before breastfeeding following an MRI scan. ^{(ACR 2026 p98, Bookwalter 2025, Mattsson 2021, ESUR 2018, ACOG 2017, Puac 2017, Cova 2014, Quintana 2014, Patenaude 2014, Sachs 2013, Tremblay 2012, Wang 2012, Chen 2008, Newman 2007, Webb 2005)}

Some authors and professional societies recommend avoiding gadolinium-based contrast agents with a high risk of nephrogenic systemic fibrosis in breastfeeding women, especially during the neonatal period—specifically gadoversetamide, gadodiamide, and gadopentetate—and instead choosing low-risk agents such as gadoterate, gadoteridol, and gadobutrol. ^{(Puac 2017, Quintana 2014, EMA 2010)}

See below the information of this related product:

• (Gadolinium-Based RMI Contrast Agents) (Safe product and/or breastfeeding is the best option.)